Pipeline
CellBion's Radiopharmaceutical Pipeline Portfolio
Clinical Stage
Clinical Stage
Development Stage
Development Stage
177Lu-PSMA-DGUL
Compared to other PSMA drugs, DGUL contains a very short linker containing a Thiouera bond
Ⅰ. Excellent stability against drug metabolism
  A.Since there is no amide bond, the drug is very stable in the body
Ⅱ. Lower Side effects!
  A. Due to the very short hydrophilic linker, drugs that are not internalized to the targeted cancer are quickly excreted from the body through the kidneys, resulting in fewer side effects

Baseline
PSA level : 823

After 2nd Cycle
PSA level : 0.33

After 4th Cycle
PSA level : 0.2

mPERCIST
In Patients with measurable disease at baseline n=9
Complete Response *
Partial Response *
Stable Disease *
Progressive disease *
Unknown *
RECIST
In Patients with measurable disease at baseline n=4
Complete Response *
Partial Response *
Stable Disease *
Progressive disease *
Unknown *

For further information regarding the interim data of mPERCIST and RECIST,
we kindly request you to contact Seungtae On Pharm.D. at the following email address:
Seungtae.on@cellbion.co.kr


99mTc-MSA-ICG - Intra-operative color and fluorescence imaging system(ICFIS)
- Check images 15 minutes after injection
- Maintain images for up to 4 hours after injection
퀵메뉴열기